Quibim partners with Highlight Therapeutics to advance immunotherapy in melanoma

Tags: AICancerimaging biomarkersInmuno-oncologyMedical Imaging
Quibim Highlight Therapeutics


  • Global leader in medical imaging analysis Quibim has joined Highlight Therapeutics, a clinical-stage company specializing in immuno-oncology, to assess efficacy of new immunotherapy treatments in advanced melanoma skin cancer using AI.
  • The algorithm developed by Quibim enables to analyze the information contained in imaging scans and correlate these findings with biological changes in patients who are treated with pembrolizumab and BO-112, an investigational medical product that may boost tumor response.
  • The results of the trial will bring much needed evidence on those patients who may benefit the most from the new approach and improve treatment for one of the most impacting cancers worldwide.


Quibim is deploying its whole-body imaging ecosystem powered by AI to help assess efficacy of BO-112, a synthetic double stranded RNA that is administered as intratumoral therapy in advanced melanoma in a new Phase II clinical trial. Global incidence of melanoma has reached epidemic proportions and cases are expected to grow to almost half a million by 2040, according to the World Health Organization.

The study, which was launched earlier this year in Spain, will shed light on immunotherapy, an emerging therapeutic approach that helps the immune system fight cancer. The outcome will help overcome current pitfalls in treatment response evaluation, according to Dr. Sonia Macia, Medical Director of Highlight Therapeutics.

We are facing the unmet medical need of treating patients who have developed progressive disease to immunotherapy,” she said. “We will try to overcome this resistance by adding BO-112 to pembrolizumab, an approved anti-PD1 drug, which is currently indicated in the treatment of several solid tumors.

Using imaging biomarkers to assess response

Assessing efficacy in terms of response rate and correlating it with tumor biomarkers will help better understand different patterns of response, a task that remains challenging in immunotherapy, especially with intratumoral treatments.

The study will draw on Quibim’s experience in correlating radiomic signatures with immunohistochemistry biomarkers to identify those patients who will benefit the most from immunotherapy.

Radiomic signatures
Radiomic signatures


Confirming the biological changes in injected lesions and correlating these findings with imaging features may help us predict which patients will have a better response to therapy,” Dr. Macia said.“Quibim is committed to the discovery of new imaging biomarkers that can later be applied in clinical practice,” Dr. Ángel Alberich-Bayarri, Quibim CEO and Co-founder, said. “Oncology and more specifically immunotherapy are key areas where quantitative imaging plays a pivotal role. Having objective measures can help improve the evaluation of treatment response and save lives, by identifying early on who will benefit the most from a specific approach.

Quibim provides a whole-body imaging ecosystem to help advance knowledge in some of the most impacting cancers, by looking at risk prediction, early diagnosis and evaluation of treatment response and recurrence risk.

Partners use the Quibim Precision® ecosystem to track the efficacy of oncolytic viruses, another immunotherapy approach that uses viruses to infect and destroy cancer cells, to defeat head and neck squamous cell carcinoma.

Quibim Precision is also being used to improve personalized treatment of breast cancer, the second leading cause of cancer death in women in the world, and predicting risk of developing pancreatic cancer, which remains challenging to diagnose.

Quibim recently received 510(k) clearance by the US Food and Drug Administration (FDA) for its QP-Prostate AI tool, which aids in the process of prostate magnetic resonance imaging reporting from visualization to quantification with the aim of increasing diagnostic accuracy and, potentially, early prostate cancer.

Quibim is leading key projects that have received €30M funding from the European Commission to help advance knowledge of pediatric, prostate, breast, colorectal and lung cancer.

About Quibim

Quibim, a company with its headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis. Quibim products are used worldwide by leading research teams. Partners use Quibim Precision®, a whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of novel treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. We understand every body part. We speak human.

About Highlight Therapeutics

Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immune-oncology. Their lead-drug candidate BO-112 is a best-in-class RNA-based therapy, which has been demonstrated to initiate a powerful treatment response.